Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (åpner nytt vindu)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Kilde‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Arkiv‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (åpner nytt vindu)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (åpner nytt vindu)

Banan M.

Kilde‎: Ann Hematol 2013;92(3):289-99.

Arkiv‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (åpner nytt vindu)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (åpner nytt vindu)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Kilde‎: Transfusion 2007;47(10):1830-6.

Arkiv‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (åpner nytt vindu)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (åpner nytt vindu)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Kilde‎: Blood 1996;87(3):887-92.

Arkiv‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (åpner nytt vindu)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (åpner nytt vindu)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Kilde‎: Iran J Blood Cancer 2009;1(4):147-50.

Arkiv‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (åpner nytt vindu)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (åpner nytt vindu)

Karimi M, Cohan N, Pishdad P.

Kilde‎: Hematology 2015;20(1):53-7.

Arkiv‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (åpner nytt vindu)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (åpner nytt vindu)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Kilde‎: Int J Hematol 2012;95(1):51-6.

Arkiv‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (åpner nytt vindu)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (åpner nytt vindu)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Kilde‎: Hemoglobin 2014;38(2):115-8.

Arkiv‎: PubMed 24471558

DOI‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (åpner nytt vindu)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (åpner nytt vindu)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Kilde‎: Blood 2013;121(12):2199-212.

Arkiv‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (åpner nytt vindu)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (åpner nytt vindu)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Kilde‎: Sci Rep. 2022;12(1):2752.

Arkiv‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (åpner nytt vindu)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (åpner nytt vindu)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Kilde‎: Haematologica 2004;89(10):1172-8.

Arkiv‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (åpner nytt vindu)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (åpner nytt vindu)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Kilde‎: Arch Iran Med 2009;12(3):295-7.

Arkiv‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (åpner nytt vindu)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (åpner nytt vindu)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Kilde‎: Eur J Haematol 1996;56(5):326-8.

Arkiv‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (åpner nytt vindu)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (åpner nytt vindu)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Kilde‎: J Matern Fetal Med 1999;8(1):1-7.

Arkiv‎: PubMed 10052837

DOI‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (åpner nytt vindu)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (åpner nytt vindu)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Kilde‎: Acta Haematol 2004;111(4):189-95.

Arkiv‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (åpner nytt vindu)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (åpner nytt vindu)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Kilde‎: Ann Hematol 2001;80(8):492-5.

Arkiv‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (åpner nytt vindu)

Fetal globin induction--can it cure beta thalassemia? (åpner nytt vindu)

Perrine SP.

Kilde‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Arkiv‎: PubMed 16304357

DOI‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (åpner nytt vindu)